header-bd-logo.svg
  • Products
  • Solutions
  • Knowledge Centre
    • Literature
    • Events
    • Training
  • Support
  • About BD
    • Our Company
      • About Us
      • Segments
      • Ethics and Compliance
    • Cybersecurity at BD
    • ESG (Environmental, Social, and Governance)
      • Global Health
      • Sustainability
      • Social Investing
      • Inclusion, Diversity & Equity
    • Innovation at BD
      • Overview
      • BD Idea Submission Process
    • Policies, Guidelines and Statements Center
    • Suppliers
      • Corporate Policies and Expectations
      • Doing Business with BD
      • Global Procurement
      • Supplier Programs
    • News, Media & Blogs
  • Careers
  • header-flag-icon-boosted-blue.svg

    India

    • North America
      • Canada (FR)
      • Canada (EN)
      • Mexico
      • United States
    • South America
      • Argentina
      • Brasil
      • Chile
      • Colombia
    • Europe
      • Belgium (FR)
      • Belgium (NL)
      • Česká republika
      • Denmark
      • Europe
      • Suomi
      • France
      • Deutschland
      • Hebrew
      • Hungary (EN)
      • Hungary (HU)
      • United Kingdom
      • Ireland
      • Italia
      • Nederland
      • Norge
      • Polska
      • Россия
      • España
      • Sverige
      • Schweiz
      • Türkiye
      • United Kingdom
    • Middle East / Africa
      • Middle East, North Africa
      • Africa
    • Asia / Pacific
      • Australia / New Zealand
      • 中国
      • Greater Asia
      • India
      • Indonesia
      • 日本
      • Korea
      • Malaysia
      • Philippines
      • Singapore
      • Thailand
      • Vietnam
  • header-flag-icon-boosted-blue.svg

    India

    North America
    • Canada (FR)
    • Canada (EN)
    • Mexico
    • United States
    South America
    • Argentina
    • Brasil
    • Chile
    • Colombia
    Europe
    • Belgium (FR)
    • Belgium (NL)
    • Česká republika
    • Denmark
    • Europe
    • Suomi
    • France
    • Deutschland
    • Hebrew
    • Hungary (EN)
    • Hungary (HU)
    • United Kingdom
    • Ireland
    • Italia
    • Nederland
    • Norge
    • Polska
    • Россия
    • España
    • Sverige
    • Schweiz
    • Türkiye
    • United Kingdom
    Middle East / Africa
    • Middle East, North Africa
    • Africa
    Asia / Pacific
    • Australia / New Zealand
    • 中国
    • Greater Asia
    • India
    • Indonesia
    • 日本
    • Korea
    • Malaysia
    • Philippines
    • Singapore
    • Thailand
    • Vietnam
true
Products

MaxPlus™ and MaxZero™ Needle-free Connector

Demonstrated in 10 peer-reviewed published studies to reduce catheter-related complications

maxzero-maxplus-hero.jpg
Loading
  1. Overview
  2. Results and Clinical Studies
  3. Products & Accessories
  4. eIFU & Resources
Overview

The MaxPlus™ and MaxZero™ Needle-free Connector technology is designed to help reduce the risk of infections and occlusions.

Features and Benefits

The differentiated MaxPlus™ and MaxZero™ Needle-free Connector technology has been helping facilities reduce central line-associated bloodstream infections (CLABSIs) and occlusions for over 10 years1–10

 Nam sodales urna sed

lower risk of CLABSI1

The MaxPlus™ Needle-free Connector was shown to reduce the risk of CLABSI by 63%, compared to other needle-free connectors, in a 2014 meta-analysis published in the American Journal of Infection Control1

Sodales urna sed

reduction in occlusions2

In a retrospective observational study of 720 home infusion patients, the MaxZero™ Needle-free Connector reduced PICC^ occlusion rates by 55.1% (p=0.001), compared to a leading neutral displacement connector2

^ PICC: Peripherally Inserted Central Catheter.

Others claim to reduce CLABSIs. We let the clinical evidence speak for us.

img

The BD MaxPlus™ Needle-free Connector is the only needle-free connector with an FDA-cleared label statement demonstrating a reduction in CLABSIs11

 

2013 CMS Hospital Compare data reported by 3,075 U.S. hospitals, accounting for nearly 11,000 CLABSIs associated with nearly 10 million catheter days, show that hospitals using the MaxPlus™ Needle-free Connector had lower unadjusted CLABSI rates, as well as lower standardized infection ratios, compared to hospitals not using the MaxPlus™ Needle-free Connector.1,3

Not all connectors are created equal

Explore the design innovations that differentiate MaxPlus™ and MaxZero™ Needle-free Connector technology—and how they can help you reduce catheter-related complications, compared to other needle-free connector designs

Upgrade to clinically proven needle-free connectors1–10 and catheters14,15

The needle-free connector you choose impacts the rate of catheter-related complications in your facility.16,17 Refer to our clinical evidence compendium for real-world evidence of helping facilities reduce catheter-related complications.1-10 Explore the design innovations that differentiate MaxPlus™ and MaxZero™ Needle-free Connector technology—and how they can help you reduce catheter-related complications, compared to other needle-free connector designs.

BD Vascular Access Management AllPoints™ Assessments

Our powerful evidence-based assessments, with analytics and benchmarks, are the first phase of BD Vascular Access Management—and the first step on the path to help you reduce complications and improve patient care.

  • Learn more forward arrow
clinician-discussion.jpg

Related Solutions

  • content_card_image

    MaxPlus™ Needle-free Connector

    the only needle-free connector with an FDA-cleared label statement demonstrating a reduction in CLABSIs
  • content_card_image

    MaxZero™ Needle-free Connector

    the same technology in a smaller size, with lower weight and reduced priming volume
  • content_card_image

    Supported by a variety of extension sets

    to help customize infusion therapy for all patients
  • content_card_image

    BD Nexiva™ Closed IV Catheter System with the MaxZero™ Needle-free Connector

    Closed integrated catheters and positive displacement needle-free connectors as part of a bundle, extended the catheters’ complication-free dwell time*,†
  • Evidence-based guidelines recommending the use of needle-free connectors

    quote-icon

    Evaluate published outcomes of infection risks associated with each type of needleless connector

    when making product purchase decisions, focusing on risks, benefits and educational requirements.

    —

    Infusion Nurses Society (INS) 2021 Infusion Therapy Standards of Practice12


    quote-icon

    Use needleless connectors (NC) as IV connection devices.

    Use a luer-lock mechanism to ensure a secure junction when attaching NC to a VAD or access site. Avoid three-way stopcocks as IV connection devices.

    —

    International Nosocomial Infection Control Consortium (INICC) 2017 Care Bundles to Prevent Central and Peripheral Line-Related Bloodstream Infections13


    Explore the results and clinical studies below to learn more about the evidence supporting MaxPlus™ and MaxZero™ Needle-free Connector technology

    63-lower-risk-clabsis.jpg
    Meta-analysis

    The MaxPlus™ Needle-free Connector was shown to reduce the risk of CLABSI by 63%, compared to other needle-free connectors, in a 2014 peer-reviewed meta-analysis reporting on 7 studies, published in the American Journal of Infection Control,1 and is associated with lower CLABSI risk, independent of seasonality, case mix index, infusion care and cleaning practices.1

    lower-clabsis-infection-ratios.jpg
    Systematic review

    A systematic review of 2013 CMS Hospital Compare data from 3,074 hospitals, accounting for nearly 11,000 CLABSIs associated with nearly 10 million catheter days, shows that hospitals using the MaxPlus™ Needle-free Connector had lower unadjusted CLABSI rates, as well as lower standardized infection ratios, compared to hospitals not using the MaxPlus™ Needle-free Connector.1

     

    55-reduction-occlusions.jpg
    Retrospective/Prospective Occlusion Study

    In a retrospective observational study of 720 home infusion patients, the MaxZero™ Needle-free Connector reduced PICC occlusion rates by 55.1% (p=0.001), compared to a leading neutral displacement connector.2 There was a 55.1% reduction in the total number of nurse visits per 100 central line-days and a 56.4% reduction in Alteplase use and associated cost, after patients were switched to the MaxZero™ Needle-free Connectors.2

    70-reduction-clabsis-pediatric.jpg
    Retrospective/Prospective CLABSI Studies

    A multidisciplinary evidence-based initiative consisting of a CVL insertion, access and maintenance bundle, including implementation of the MaxPlus™ Needle-free Connector, resulted in a reduction in CLABSIs from an estimated 7.8 CLABSIs per 1000 catheter days to 2.3 CLABSIs per 1000 catheter days.4

    reduced-clabsis-icu.jpg
    Retrospective/Prospective CLABSI Studies

    An ICU in a suburban Baltimore hospital reduced CLABSI rates to zero in 2012, by revising its CVAD policies and initiatives and implementing a bundled approach, including the use of MaxPlus™ Needle-free Connectors.5

    Manual entered skus

    Other products you might be interested in

    • Swabstick
    • Related Product Family 02
    • Related Product Family 03
    • Related Product Family 04
    Resources
    Case-Study.png
    Case Studies

    BD promotes clinical excellence by providing various infusion resources on best practices, clinical innovations and industry trends.

    Learn more
    Event Icon
    Literature

    BD's collection of literature on our infusion offerings gives you information you can use to continue striving for excellence.

    Learn more
    Training-Icon1.png
    Training

    BD offers infusion training resources to help improve your clinical practices as part of our goal of advancing the world of health.

    Learn more
    Event Icon
    Events

    BD supports and attends healthcare industry events with market-leading products and services that aim to improve care while lowering costs.

    Learn more

    Please let us know the areas that you are interested in:

    MaxPlus™ and MaxZero™ Needle-free Connector
    Ready to learn more? Let’s have a conversation.
    Reference
    1. Tabak YP, Jarvis WR, Sun X, Crosby CT, Johannes RS. Meta-analysis on central line-associated bloodstream infections associated with a needleless intravenous connector with a new engineering design. Am J Infect Control. 2014;42(12):1278–1284. doi: 10.1016/j.ajic.2014.08.018.
    2. Williams A. Catheter occlusion in home infusion: the influence of needleless connector design on central catheter occlusion. J Infus Nurs. 2018;41(1):52–57. doi: 10.1097/NAN.0000000000000259.
    3. Tabak YP, Johannes RS, Sun X, Crosby CT, Jarvis WR. Innovative use of existing public and private data sources for postmarketing surveillance of central line-associated bloodstream infections associated with intravenous needleless connectors. J Infus Nurs. 2016;39(5):328–335. doi: 10.1097/NAN.0000000000000185.
    4. Costello JM, Morrow DF, Graham DA, Potter-Bynoe G, Sandora TJ, Laussen PC. Systematic intervention to reduce central line-associated bloodstream infection rates in a pediatric cardiac intensive care unit. Pediatrics. 2008;121(5):915–923. doi: 10.1542/peds.2007-1577.
    5. Wallace MC, Macy DL. Reduction of central line-associated bloodstream infection rates in patients in the adult intensive care unit. J Infus Nurs. 2016;39(1):47–55. doi: 10.1097/NAN.0000000000000151.
    6. Sandora TJ, Graham DA, Conway M, Dodson B, Potter-Bynoe G, Margossian SP. Impact of needleless connector change frequency on central line-associated bloodstream infection rate. Am J Infect Control. 2014;42(5):485–489. doi: 10.1016/j.ajic.2014.01.022.
    7. Royer T. Implementing a better bundle to achieve and sustain a zero central line-associated bloodstream infection rate. J Infus Nurs. 2010;33(6):398–406. doi: 10.1097/NAN.0b013e3181f8586b.
    8. Casey AL, Karpanen TJ, Nightingale P, Chaganti S, Elliott TSJ. Microbiologic contamination of a positive- and a neutral-displacement needleless intravenous access device in clinical use. Am J Infect Control. 2016;44(12):1678–1680. doi: 10.1016/j.ajic.206.06.027.
    9. Clavier T, Ferguen M, Gouin P, et al. Impact of MaxZero™ needle-free connector on the incidence of central venous catheter-related infections in surgical intensive care unit. Aust Crit Care. 2019;32(2):107–111. doi: 10.1016/j.aucc.2018.03.003.
    10. Hankins R, Majorant OD, Rupp ME, et al. Microbial colonization of intravascular catheter connectors in hospitalized patients. Am J Infect Control. 2019;47(12):1489–1492. doi: 10.1016/j.ajic.2019.05.024.
    11. BD MaxPlus™ Needle-free Connector Directions for Use. 630-00658; 2015.
    12. Gorski LA, Hadaway L, Hagle ME, et al. Infusion Therapy Standards of Practice, 8th Edition. J Infus Nurs. 2021;44(1S,1):S1–S224. doi: 10.1097/NAN.0000000000000396.
    13. International Nosocomial Infection Control Consortium (INICC) Care bundles to prevent central and peripheral line-related bloodstream infections. INICC website. http://www.inicc.org/media/docs/2017-INICCBSIPreventionGuidelines.pdf. Published January 1, 2017. Accessed June 2, 2021.
    14. González López J, Arribi Vilela A, Fernández Del Palacio E, et al. Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. J Hosp Infect. 2014;86(2):117–126. doi: 10.1016/j.jhin.2013.10.008.
    15. Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabilization systems. J Infus Nurs. 2010;33(6):371–384.doi: 10.1097/NAN.0b013e3181f85be2.
    16. Hadaway L. Needleless connectors for IV catheters. Am J Nurs. 2012;112(11):32–44. doi: 10.1097/01.NAJ.0000422253.72836.c1.
    17. Curran E. Needleless connectors: the vascular access catheter’s microbial gatekeeper. J Infect Prev. 2016;17(5):234–240. doi: 10.1177/1757177416657164.
    18. † Guenezan J, Marjanovic N, Drugeon B, et al. Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, single centre, randomised-controlled, two-by-two factorial trial. Lancet Infect Dis. 2021. doi: 10.1016/S1473-3099(20)30738-6.

    * Compared to the standard of care that included a standard peripheral catheter and three way stopcock among other elements.

    BD-25572 (01/23)  

    • Follow us
      • Linked In
      • Facebook
      • X
      • Youtube
    Quick Links
    • Product complaint
    • Electronic Instructions for Use
    • Investors
    • Suppliers
    • Our Company
    • Innovation
    • Environmental, Social, and Governance
    • Ethics and Compliance
    • Careers
    • Cybersecurity
    • Contact us
    • Cookie Preferences
    • Privacy
    • Terms of Use
    • Website Accessibility
    BD_tag_en_1-Color_Reverse_RGB_TransparentBurst

    © 2025 BD. All rights reserved. BD and the BD Logo are trademarks of Becton, Dickinson and Company. All other trademarks are the property of their respective owners.

    true
    Request Documents Clear All
    MaxPlus™ and MaxZero™ Needle-free Connector Demonstrated in 10 peer-reviewed published studies to reduce catheter-related complications BD MaxPlus™ /content/dam/bd-assets/bd-com/en-us/logos/bd/header-bd-logo.svglogo

    Demonstrated in 10 peer-reviewed published studies to reduce catheter-related complications

    /en-in/products-and-solutions/products/product-brands/maxplus-and-maxzero-needle-free-connector